Patents by Inventor Jeremy Roach

Jeremy Roach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
    Publication number: 20230226040
    Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
    Type: Application
    Filed: November 21, 2022
    Publication date: July 20, 2023
    Inventors: Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230144051
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 11, 2023
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230114765
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 13, 2023
    Inventors: Zhenwu Li, Zhiyong YU, Jeremy Roach, Gia Hoang, Bin HU, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11566028
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 31, 2023
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Jeremy Roach, Wenqing Yao
  • Synthesis of 20-nor-salvinorin A
    Patent number: 11512075
    Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 29, 2022
    Assignee: The Scripps Research Institute
    Inventors: Ryan Shenvi, Jeremy Roach, Yusuke Sasano, Laura Bohn, Cullen Schmid
  • IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20220315595
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: June 9, 2022
    Publication date: October 6, 2022
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 11459329
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: October 4, 2022
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 11427592
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 30, 2022
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210214366
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 14, 2021
    Publication date: July 15, 2021
    Inventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210115053
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 22, 2021
    Inventors: Artem Shvartsbart, Jeremy Roach, Wenqing Yao
  • IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200199131
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • SYNTHESIS OF 20-NOR-SALVINORIN A
    Publication number: 20200131162
    Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 30, 2020
    Inventors: Ryan Shenvi, Jeremy Roach, Yusuke Sasano, Laura Bohn, Cullen Schmid